FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Vashington,	D.C.	20549	
vasimigton,	D.O.	200-0	

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OIVID APPROVAL										
OMB Number:	3235-0287									
Estimated average burder	n									
hours per response.	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LAWLOR AUGUSTINE</u>						2. Issuer Name and Ticker or Trading Symbol LEAP THERAPEUTICS, INC. [LPTX]								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner						
	P THERA	First) PEUTICS, INC. FREET SUITE I				3. Date of Earliest Transaction (Month/Day/Year) 11/14/2017								X	X Officer (give title other (specify below) Chief Operating Officer					
(Street) CAMBR (City)		IA State)	02141 (Zip)		_	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Indi	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(=::9)			able I - No	n-De	rivat	tive S	ecurities	s Ac	guired	Dis	posed o	of, or B	enef	icially (Owned					
1. Title of Security (Instr. 3) 2. Trans Date (Month/I		nsacti	on 2A. Deemed Execution Date,		3. Transaction Code (Instr.		red (A)	or 5. Amount of Securities Beneficially Owned Follow		,	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership							
										v	Amount	(A) or (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock 11/2			14/20	2017		P		1,057,769		A	\$6.085	3,573,376				See Footnote ⁽¹⁾				
Common Stock													2,618,406		I		See Footnote ⁽²⁾			
Common Stock														343,889		I		See cootnote ⁽³⁾		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, Tracecurity or Exercise (Month/Day/Year) if any Co		Transa Code (5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		A)	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am Securities Und Derivative Sec (Instr. 3 and 4)			lerlying urity	rlying Derivative		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		11. Nature of Indirect Beneficial Ownership (Instr. 4)					
				C	Code	v	(A)		Date Exercisal		Expiration Date	Title	Nui			(Instr. 4)				
Warrant (Right to Buy)	\$6.085	11/14/2017			P		1,057,769		11/14/20	17 1	11/14/2024	Stock, \$0.001 par value	1,0	057,769	(4)	1,057,	7,769 I		See footnote ⁽¹⁾	

Explanation of Responses:

- 1. The shares are owned directly by HealthCare Ventures IX, L.P. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCVIX Directors") are the Managing Directors of HealthCare Partners IX, LLC ("HCPIX LLC"), which is the General Partner of HealthCare Partners IX, L.P. Each of the HCVIX Directors, HCPIX LLC and HCPIX beneficially own and share voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. Augustine Lawlor disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.
- 2. The shares are owned directly by HealthCare Ventures VIII, L.P. Christopher K. Mirabelli, James H. Cavanaugh, John W. Littlechild, Harold Werner and Augustine Lawlor (collectively, the "HCVVIII Directors") are the Managing Directors of HealthCare Partners VIII, L.P. ("HCPVIII"), which is the General Partner of HealthCare Partners VIII, L.P. ("HCPVIII"), which is the General Partner of HealthCare Ventures VIII, L.P. Each of the HCVVIII Directors, HCPVIII LLC and HCPVIII beneficially own and share voting and dispositive power with respect to all of the securities owned by HealthCare Ventures VIII, L.P. Augustine Lawlor disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities.
- 3. The shares are owned directly by HealthCare Ventures Strategic Fund, L.P. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor (collectively, the "HCSP Directors") are the Managing Directors of HealthCare Strategic Partners, LLC ("HCV Strategic LLC"), which is the General Partner of HealthCare Ventures Strategic Fund, L.P. Each of the HCSP Directors, and HCV Strategic LLC beneficially own and share voting and dispositive power with respect to all of the securities owned by HCV Strategic Fund, L.P. Augustine Lawlor disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary
- 4. The reported securities were included with the 1,057,759 shares of common stock purchased by HealthCare Ventures IX, L.P. for \$6.085 per share. Each such purchased share of common stock was issued with a warrant to purchase one share of common stock

/s/ Douglas E. Onsi, as attorney-11/16/2017 in-fact for Augustine Lawlor ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.